In this report we directly compare the in vivo and in vitro MRI properties of gadolinium-dendrimer conjugates of derivatized acyclic diethylenetriamine-N,N',N',N'',N''-pentaacetic acid (1B4M-DTPA) and macrocyclic 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (C-DOTA). The metal-ligand chelates were pre-formed in alcohol prior to conjugation to the generation 4 PAMAM dendrimer (G4D), and the dendrimer-based agents were purified by Sephadex(R) G-25 column. The analysis and SE-HPLC data indicated chelate to dendrimer ratios of 30:1 and 28:1, respectively. Molar relaxivity measured at pH 7.4, 22 degrees C, and 3T are comparable (29.5 vs 26.9 mM(-1)s(-1)), and both conjugates are equally viable as MRI contrast agents based on the images obtained. The macrocyclic agent however exhibits a faster rate of clearance in vivo (t(1/2)=16 vs 29 min). Our conclusion is that the macrocyclic-based agent is the more suitable agent for in vivo use for these reasons combined with kinetic inertness associated with the Gd(III) DOTA complex stability properties. Published by Elsevier Ltd.
In this report we directly compare the in vivo and in vitro MRI properties of gadolinium-n class="Chemical">dendrimer conjugates of derivatized acyclicdiethylenetriamine-N,N',N',N'',N''-pentaacetic acid (1B4M-DTPA) and macrocyclic 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (C-DOTA). The metal-ligand chelates were pre-formed in alcohol prior to conjugation to the generation 4 PAMAMdendrimer (G4D), and the dendrimer-based agents were purified by Sephadex(R) G-25 column. The analysis and SE-HPLC data indicated chelate to dendrimerratios of 30:1 and 28:1, respectively. Molar relaxivity measured at pH 7.4, 22 degrees C, and 3T are comparable (29.5 vs 26.9 mM(-1)s(-1)), and both conjugates are equally viable as MRI contrast agents based on the images obtained. The macrocyclic agent however exhibits a faster rate of clearance in vivo (t(1/2)=16 vs 29 min). Our conclusion is that the macrocyclic-based agent is the more suitable agent for in vivo use for these reasons combined with kinetic inertness associated with the Gd(III) DOTA complex stability properties. Published by Elsevier Ltd.
Authors: Jolanta F Kukowska-Latallo; Kimberly A Candido; Zhengyi Cao; Shraddha S Nigavekar; Istvan J Majoros; Thommey P Thomas; Lajos P Balogh; Mohamed K Khan; James R Baker Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: P M Parizel; H R Degryse; J Gheuens; J J Martin; M Van Vyve; C De La Porte; P Selosse; P Van de Heyning; A M De Schepper Journal: J Comput Assist Tomogr Date: 1989 May-Jun Impact factor: 1.826
Authors: R H Knop; J A Frank; A J Dwyer; M E Girton; M Naegele; M Schrader; J Cobb; O Gansow; M Maegerstadt; M Brechbiel Journal: J Comput Assist Tomogr Date: 1987 Jan-Feb Impact factor: 1.826
Authors: Heng Xu; Celeste A S Regino; Marcelino Bernardo; Yoshinori Koyama; Hisataka Kobayashi; Peter L Choyke; Martin W Brechbiel Journal: J Med Chem Date: 2007-06-07 Impact factor: 7.446
Authors: Ana Christina Opina; Karen J Wong; Gary L Griffiths; Baris I Turkbey; Marcelino Bernardo; Takahito Nakajima; Hisataka Kobayashi; Peter L Choyke; Olga Vasalatiy Journal: Nanomedicine (Lond) Date: 2014-11-13 Impact factor: 5.307
Authors: Derek J Averill; Joel Garcia; Buddhima N Siriwardena-Mahanama; Sashiprabha M Vithanarachchi; Matthew J Allen Journal: J Vis Exp Date: 2011-07-21 Impact factor: 1.355
Authors: Christopher M Andolina; Piper J Klemm; William C Floyd; Jean M J Fréchet; Kenneth N Raymond Journal: Macromolecules Date: 2012-11-12 Impact factor: 5.985
Authors: Francesca J Nicholls; Matthew W Rotz; Harmanvir Ghuman; Keith W MacRenaris; Thomas J Meade; Michel Modo Journal: Biomaterials Date: 2015-11-14 Impact factor: 12.479
Authors: Michael B Winter; Piper J Klemm; Christine M Phillips-Piro; Kenneth N Raymond; Michael A Marletta Journal: Inorg Chem Date: 2013-02-08 Impact factor: 5.165